{"disease":{"id":"anti-programmed-cell-death-receptor-1","name":"anti programmed cell death receptor 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05311566","title":"PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":92,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05310383","title":"Tislelizumab and Radiotherapy for Recurrent Cervical Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"Lei Li","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}